Wang C, Zhou Y, Lin Y, Mao F, et al. Rationale and design of a phase II trial of pyrotinib in combination with nab-paclitaxel as adjuvant therapy for N0/N1mi, HER2 + early breast cancer (PHAEDRA). BMC Cancer 2022;22:269.
PMID: 35287613